Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B

Journal of Viral Hepatitis

Volumn 8, Issue 4, 2001, Pages 270-275

  Buti, M ^a,b   Cotrina, M ^a,b   Jardi, R ^a,b   De Cruz Castro, E ^a,b   Rodriguez Frias, F ^a,b   Sanchez Avila F ^a,b   Esteban, R ^a,b   Guardia, J ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b Glaxo Wellcome   (Spain)

Author keywords

Anti HBe positive chronic hepatitis B; Hepatitis B; Lamivudine; Lamivudine resistant variants

Indexed keywords

ALANINE AMINOTRANSFERASE; DNA POLYMERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; LAMIVUDINE;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HEPATITIS B; HUMAN; MALE; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PILOT PROJECTS; POLYMERASE CHAIN REACTION; VIRUS REPLICATION;

EID: 0034913708     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2001.00296.x     Document Type: Article

References (31)

1. Hepatitis B e antigen negative chronic hepatitis B from clinical recognition to pathogenesis and treatment
2. Precore mutant hepatitis B virus infection and liver disease
3. Natural course and response to interferon of chronic hepatitis B accompanied by antibodies to hepatitis B e antigen
4. Long-term response to therapy of chronic anti-HBe positive hepatitis B is poor independent of type and schedule of interferon
5. Side effects of alpha interferon
6. A preliminary trial of lamivudine for chronic hepatitis B infection
7. Lamivudine therapy for chronic hepatitis B. A six-month randomized dose-ranging study
8. A one-year trial of lamivudine for chronic hepatitis B
9. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis surface antigen carriers: A placebo-controlled trial
10. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine
11. Efficacy of lamivudine in patients with hepatitis B e antigen-negative B virus DNA-positive (precore mutant) chronic hepatitis B
12. Long-term follow-up of patients with anti-HBe/HBV-DNA-positive chronic hepatitis B treated for 12 months with lamivudine
13. Post lamivudine treatment follow-up of patients with HBeAg negative chronic hepatitis B
14. Hepatitis B virus infection: Precore mutants and its relation to viral genotypes
15. Transient emergence of Hepatitis B Variants a patient with chronic hepatitis B resistant to lamivudine
16. Extended lamivudine retretament for chronic hepatitis B. Maintenance of viral suppression after discontinuation of therapy
17. Lamivudine as initial treatment for chronic hepatitis B in the United States
18. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B
19. Long-term therapy of chronic hepatitis B with lamivudine
20. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
21. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
22. Drug therapy for chronic hepatitis B antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy
23. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
24. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo
25. Three year lamivudine therapy in chronic HBV
26. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
27. Incidence, characteristics and clinical impact of lamivudine resistance in chronic hepatitis B
28. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns
29. Identification of HBV variants which cannot produce pre-core derived HBeAg and may be responsible for severe hepatitis
30. Hepatitis B virus precore/core variation and interferon therapy
31. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy